This report extends our understanding of the interaction between EBV and host innate 36 responses. It provides the first evidence that the susceptibility to NK cell lysis of EBV 37 infected B cells undergoing lytic replication is dependent upon the phase of lytic cycle.
38
Induction of lytic cycle is associated with acquired sensitization to NK cell killing, while 39 progress through late lytic cycle is associated with acquired resistance to killing. We 
97
In the present study we identified the immediate-early protein, BZLF1, as being able to 98 sensitize cells to NK cell killing through upregulating the ULBP NKG2D ligands. We 
Materials and Methods

107
Cell lines
108
The NK cell line NKL (15) was maintained in RPMI 1640 supplemented with 10% 
119
DG75-control and DG75-BHRF1 were generated through transduction and NGFR-120 sorting as described above and maintained in RPMI 1640 supplemented with 8% FCS.
121
A doxycycline (DOX)-inducible BZLF1 expression vector, pRTS-CD2-BZLF1, or 122 control vector with the reverse BZLF1 sequence (pRTS-CD2-control) (27) were 
Flow cytometry analysis
170
Stained cell samples were detected on BDbiosciences Accuri C6 Flow Cytometer.
171
Data were analyzed using FlowJo software (TreeStar). washed three times before use as effectors in cytotoxicity assays.
187
In 16h cytotoxicity assays, killing was measured by determining the decline in 
Statistical analysis
212
Where statistical analysis was performed, data were analysed with student t tests or 213 one-way ANOVA as described in the figure legends. Analysis was performed using
214
Prism 5 software (Graphpad Software).
215
Results
216
The switch from latent to lytic infection sensitizes B cells to NK cell killing 217 We previously reported that the switch from latent to lytic cycle in AKBM cells induced killing by effector cells.
244
As shown in Figure 2B , with increasing effector: target ratios, the levels of caspase-3 by immunoblotting ( Figure 6B ). Finally the four cell lines were used as targets in 367 cytotoxicity assays to measure sensitivity to NK cell killing ( Figure 6C ). As expected,
368
there was no significant NK cell killing of DG75-control and DG75-BHRF1 cells. As 
373
From what is known about BHRF1, we anticipated that this vBcl-2 protects B cells 374 from NK cell killing through its anti-apoptotic function rather than by directly reversing 375 the effects of BZLF1 through downregulation of ULBPs. To rule out the latter 376 possibility, we assayed the surface expression of ULBP ( Figure 6D antibodies were included in cytotoxicity assays, they had no effect on NK cell killing of ULBP2 and MICB; while US142, US18 and US20 reduce expression of MICA (45-48).
516
UL141 blocks surface expression of DNAM-1 ligands, CD112 and CD155 (49, 50).
517
CMV also ligates NK inhibitory receptors through expression of HLA homologues such 518 as UL18 that binds LIR-1 or stabilising HLA-C through the action of UL40 (11, 51).
519
The value of extending our work beyond the AKBM model to non-malignant LCLs and significance was determined using t tests. P < 0.05(*) P < 0.01(**), P < 0.001 (***). 
